TPO-induced megakaryocytic differentiation requires strong and prolonged MAPK pathway activation, which depends on specific regions of the Mpl cytoplasmic domain and the cellular context.
No takes yet. Share an insight, caveat, or question.
Does not support clinical TPO or MEK modulation in thrombocytopenia; leaves open MAPK duration requirements in human megakaryopoiesis.
Rouyez et al. (1997) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: